Compagnie Lombard Odier SCmA’s Sarepta Therapeutics SRPT Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-800	Closed	-$24K	–	760
2017 Q1	$24K	Sell	800 -800	-50%	-$24.8K	﹤0.01%	617
2016 Q4	$44K	Hold	1,600	–	–	﹤0.01%	620
2016 Q3	$98K	Hold	1,600	–	–	﹤0.01%	576
2016 Q2	$30K	Hold	1,600	–	–	﹤0.01%	740
2016 Q1	$32K	Buy	+1,600	New	+$28K	﹤0.01%	774
2015 Q3	–	Sell	-1,300	Closed	-$40K	–	830
2015 Q2	$40K	Sell	1,300 -500	-28%	-$10.2K	﹤0.01%	661
2015 Q1	$24K	Hold	1,800	–	–	﹤0.01%	844
2014 Q4	$26K	Buy	+1,800	New	+$30.5K	﹤0.01%	678

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

TCP

Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Compagnie Lombard Odier SCmA's SRPT Position: Q2 2017 in Review

Compagnie Lombard Odier SCmA sold out of Sarepta Therapeutics (SRPT) in Q2 2017, closing a stake of 800 shares — an estimated $24K sold.

Compagnie Lombard Odier SCmA first reported a position in SRPT in Q4 2014 and held it in 8 quarters. The position peaked at $98K in Q3 2016. 189 funds tracked by Wall St. Rank hold SRPT as of Q2 2017.

Compagnie Lombard Odier SCmA reported no remaining Sarepta Therapeutics position as of Q2 2017 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 800 Sarepta Therapeutics shares in Q2 2017, an estimated $24K.
Compagnie Lombard Odier SCmA first reported a position in Sarepta Therapeutics in Q4 2014 and held it in 8 quarters.
Compagnie Lombard Odier SCmA's Sarepta Therapeutics position peaked at $98K in Q3 2016.
189 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2017.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2017, filed 14 Aug 2017.